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Organs are composed of highly differentiated, very specialized parenchy-
mal cells surrounded by stroma consisting of extracellular matrix, tissue
fluid, and undifferentiated pluripotent mesenchymal cells. Parenchymal cells
distinguish one organ from another based on their unique morphologic
features and their highly specialized functions. Disproportionate stromal
growth, relative to parenchymal growth, termed ‘‘fibrosis’’ (sclerosis or cirr-
hosis), represents a pathologic structural remodeling of an organ [1].
Fibrosis presents in several different morphologic patterns. A reparative
(replacement) fibrosis appears at sites of parenchymal cell loss. For example,
microscopic scarring of ventricular myocardium follows cardiac myocyte
necrosis [2–4], whereas a macroscopic scar follows segmental infarction
[5,6]. A perivascular fibrosis of intramural vessels with extensions into the
contiguous interstitial space has been referred to as a ‘‘reactive fibrosis’’
because loss of parenchyma is not a requisite [7]. A perivascular-interstitial
fibrosis, for example, accompanies chronic elevations in the effector hor-
mones of the renin-angiotensin-aldosterone system [8–11].
Absolute fibrosis is defined as increased collagen concentration of an
organ and consists predominantly of fibrillar collagen types I and III that
appear secondary to altered collagen turnover (synthesis greater than degra-
dation). Collectively, fibrosis is a common pathway to organ failure. This
holds true for such diverse organs as the heart [12,13], kidneys [14,15], lungs
[16,17], and liver [18].
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the repair process has been completed. This is related to fibrillar collagen
degradation by matrix metalloproteinases [19,20]. In other cases, there is
a persistent fibrosis (eg, infarct scar of the myocardium) that is essential for
organ integrity. Lastly, a progressive fibrosis can occur (eg, experimental
glomerulonephritis, chronic elevation of circulating angiotensin II [ANGII]
or aldosterone) and destroys organ architecture and accounts for its failure
[20–23]. The need to prevent fibrosis or to regress it, once formed, represents
a major challenge. Various strategies can be taken [14].
Myocardial fibrosis in hypertensive heart disease
Clinical evidence
The essential criterion in defining hypertensive heart disease (HHD) is a
greater than normal heart mass in the absence of a cause other than arterial
hypertension. It is now accepted, however, that besides left ventricular hyper-
trophy (LVH), alterations in myocardial structure as listed below account for
loss of tissue homogeneity and pathologic remodeling that appears in HHD:
Cellular alterations
Cardiomyocytes
Hypertrophy, atrophy, apoptosis, necrosis
Noncardiomyocytes
Hyperplasia and apoptosis of fibroblasts
Hypertrophy or hyperplasia of vascular smooth muscle cells
Noncellular alterations
Interstitial and perivascular fibrosis
Microscopic scarring
Medial thickening of coronary arterioles
Diminished number of capillaries
A growing body of evidence indicates that myocardial fibrosis is one of
the key pathologic features of myocardial remodeling in HHD. In fact,
a number of studies performed in postmortem human hearts [24–26] and
endomyocardial human biopsies [27–30] have shown that myocardial col-
lagen volume fraction, a morphometric measure of the amount of tissue
collagen, is constantly increased in patients with HHD compared with nor-
motensive controls (Fig. 1). Furthermore, an exaggerate accumulation of
fibrillar collagen types I and III within the myocardial interstitium and
surrounding intramural coronary arteries and arterioles has been evidenced
immunohistochemically in patients with HHD [31].
Potential mechanisms
Collagen types I and III are the major fibrillar collagens produced by
fibroblasts in the adult heart. They exhibit the characteristic triple helical
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lagen of the heart provides the structural scaffolding for cardiomyocytes and
coronary vessels and imparts cardiac tissue with physical properties that
include stiffness and resistance to deformation [12]. In addition, fibrillar
collagen may also act as a link between contractile element of adjacent
cardiomyocytes and as a conduit of information that is necessary for cell
function.
As in other organs, collagen turnover of normal adult heart results from
the equilibrium between the synthesis and degradation of collagen types I
and III molecules [32]. The synthesis of collagen molecules follows the
Fig. 1. (A) Histologic sections of interventricular septal specimen biopsies from humans.
Sections were stained with picrosirius red, and the interstitial collagen was identified in red
(original magnification 20). (B) Collagen volume fraction (CVF) determined in interventric-
ular septal specimen biopsies from humans. (Adapted from Querejeta R, Varo N, Lo´pez B,
Larman M, Artin˜ano E, Etayo JC, et al. Serum carboxy-terminal propeptide of procollagen
type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation
2000;101:1729–35; with permission.)
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proteins in that the newly formed a chains undergo a number of post-
translational modifications. Extracellular degradation of collagen fibers is
mediated by collagenase and other members of the matrix metalloprotein-
ase family of zinc-containing endoproteinases. The active form of collagenase
can be inhibited by interaction with naturally occurring specific tissue inhib-
itors of matrix metalloproteinases (TIMPs).
As shown by in vivo experiments, chronic pressure overload stimulates
both procollagen gene expression and collagen protein synthesis leading to
excessive collagen deposition and fibrosis [33]. In addition, in vitro studies
have shown that procollagen type I synthesis is stimulated in cardiac fibro-
blasts submitted to cyclic mechanical load [33]. Hemodynamic overload of
the left ventricle caused by systemic hypertension may play a role in myo-
cardial fibrosis.
Nevertheless, two types of findings suggest that besides the mechanic
factor, nonhemodynamic factors may also contribute to myocardial fibro-
sis in human hypertension. First, myocardial fibrosis has been found not
only in the left ventricle but also in the right ventricle [25,34] and the
interventricular septum [35] in postmortem studies of human hearts with
HHD. Second, recent studies have shown that the ability of antihypertensive
treatment to regress fibrosis in hypertensives with biopsy-proved myocardial
fibrosis is independent of its antihypertensive efficacy [29,36]. The current
view is that myocardial fibrosis may be the consequence of the loss of
reciprocal regulation that normally exists between molecules that stimulate
(eg, ANGII) and molecules that inhibit fibrillar collagen turnover [37].
Factors modulating collagen types I and III turnover in the myocardium
include the following:
Factors that facilitate the synthesis of collagen
Vasoactive substances
Angiotensin II, endothelin-1, catecholamines
Growth factors
Transforming growth factor-b1, platelet-derived growth factor, basic
fibroblast growth factor, insulin-like growth factor-1
Hormones
Aldosterone, deoxycorticosterone
Cytokines
Interleukin-1
Adhesion molecules
Ostepontin
Factors that facilitate the degradation of collagen
Vasoactive substances
Bradykinin, prostaglandins, nitric oxide, natriuretic peptides
Growth factors
Hepatocyte growth factor
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Glucocorticoids
Cytokines
Tumoral necrosis factor-a, interferon-c
Endogenous peptides
N-acetyl-seryl-aspartyl-lysyl-proline
An excess of stimulators, caused by either absolute stimulator over-
production or by their relative overabundance because of a deficit in inhib-
itor formation can promote fibrosis.
Clinical impact
Several arguments support the concept that myocardial fibrosis has a
particularly important influence in the process of heart failure associated
with cardiac remodeling [38]. First, interstitial fibrosis contributes to ven-
tricular wall stiffness and consequently impairs cardiac compliance, con-
tributing to impaired diastolic function. Second, because neither the collagen
network nor the fibroblasts contribute to systolic contraction, increased
collagen deposition and fibroblast volume means that systolic work is being
performed by a smaller proportion of the cardiac mass, contributing to
systolic dysfunction. Third, perivascular fibrosis leads to increased distance
that oxygen must diffuse and potentially lowers PaO2 for the working car-
diomyocytes. Finally, electrical coupling on the cardiomyocytes may be im-
paired by the accumulation of collagen proteins and fibroblasts because
such accumulation causes morphologic separation of cardiomyocytes.
Role of angiotensin II in myocardial fibrosis
Various lines of evidence support a role for ANGII as a critical candidate
factor to induce myocardial fibrosis in HHD.
In vivo evidence
Animal models
Endogenous elevations in circulating ANGII that accompany unilateral
renal artery stenosis [39] or the infusion of exogenous ANGII [40] are
associated with increased blood pressure and fibrosis. The appearance of
such fibrous tissue formation is preceded by increased expression of ANGII
type 1 (AT1) receptors, transforming growth factor-b1 (TGF-b1), and
mRNA for collagen types I and III [41]. In addition, development of fibrosis
involves proliferating fibroblasts and cell differentiation into myofibroblasts
[42]. Two observations suggest that the ability of ANGII to induce cardiac
fibrosis in these models is independent of its hypertensive action. First,
fibrosis in the renal artery stenosis model develops in both low-pressure
right and left atria and right ventricle and high-pressure left ventricle [43].
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either angiotensin converting enzyme (ACE) inhibitors or AT1 receptor
antagonists, but not hydralazine or prazosin, despite a similar antihyper-
tensive efficacy of these compounds [44,45]. The critical role of ANGII in
hypertension-associated cardiac fibrosis is further supported by the observa-
tion that experimental infrarenal aortic binding, which does not induce
ANGII, causes blood pressure elevation and cardiomyocyte hypertrophy
but not cardiac fibrosis [43].
The hypertensive Ren2 rat provides a well-established model of ANGII-
dependent cardiac hypertrophy [46]. Several studies have revealed that
interstitial and perivascular fibrosis, along with extensive collagen types I and
III deposition are present inRen2 [47–49]. Increased cardiac renin andANGII
levels have been described in this transgenic rat model [46]. In addition,
cardiac lesions are very sensitive to ACE inhibition and AT1 receptor
antagonism in Ren2 rats [50]. As a result, the development of hypertrophy
and fibrosis in the heart of these animals has been attributed, at least partially,
to a local activation of the cardiac renin-angiotensin system.
Pharmacologic studies
Experimental findings. Pharmacologic interventions with ACE inhibitors or
AT1 receptor antagonists have underscored the potential importance of
ANGII in the mediation of cardiac fibrosis in pathologic conditions, such as
primary hypertension. In rats with spontaneous hypertension and LVH,
myocardial fibrosis has been shown to regress by treatment with the ACE
inhibitor lisinopril [51]. This effect occurred independently of the drug’s
antihypertensive effect [51]. It has been found that chronic AT1 receptor
antagonism with losartan resulted in reversal of fibrosis, inhibition of the
posttranscriptional synthesis of procollagen type I, inhibition of TIMP-1
expression, and stimulation of collagenase activity in the left ventricle of
adult rats with spontaneous hypertension [52,53]. Analysis of the individual
data showed that the intensity of these myocardial changes was independent
of the antihypertensive efficacy of the drug [52,53].
Clinical findings. The fibrogenic role of ANGII in humans has been in-
vestigated in three recent prospective trials of limited size using biopsy-
proved myocardial fibrosis in patients with essential hypertension and LVH.
Schwartzkopff et al [28] studied 14 patients before and after 1 year of
treatment with the ACE inhibitor perindopril. Structural analysis revealed
diminution of perivascular and interstitial fibrosis with treatment. The ob-
served regression of fibrosis on ACE inhibitor treatment was observed in
the non–pressure-overloaded right ventricle, indicating that the antifibrotic
effect was not accounted for by left ventricular pressure reduction alone.
Brilla et al [29] randomized 35 previously treated patients with controlled
blood pressure to receive either the ACE inhibitor lisinopril or the diuretic
hydrochlorothiazide for 6 months. Only patients randomized to lisinopril
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was similar in patients treated with either lisinopril or hydrochlorothiazide.
Finally, Lo´pez et al [36] studied 37 treated patients with uncontrolled blood
pressure. After randomization, 21 patients were assigned to the AT1 receptor
antagonist losartan and 16 to the calcium channel blocker amlodipine for
12 months. Whereas myocardial fibrosis decreased significantly in losartan-
treated patients, this parameter remained unchanged in amlodipine-treated
patients. A similar reduction of blood pressure in losartan-treated patients
than in amlodipine-treated patients was reported in this study. Collectively,
these observations support the concept that in addition to pressure overload,
ANGII induces myocardial fibrosis in essential hypertension.
Cellular and molecular mechanisms
Increasing evidence strongly indicates that ANGII exerts multiple pro-
fibrotic effects within the heart including induction of fibroblast hyperplasia,
activation of collagen biosynthetic pathways, and inhibition of collagen
degradative pathways (Fig. 2). In addition, available data indicate that these
effects may result from either the direct action of ANGII or a synergistic
cooperation between this peptide and other profibrotic factors.
Stimulation of fibroblast proliferation
In vitro studies of rat and human cardiac fibroblasts have shown that
ANGII stimulates cell proliferation by the AT1 receptor [54]. Results in the
literature indicate that the proliferative response of fibroblasts to ANGII
might well be mediated by stimulation of the synthesis of growth or in-
flammatory substances like platelet-derived growth factor and cytokines,
by integrin activation caused by adhesion proteins, or by a combination of
these mechanisms [55,56].
For instance, ANGII strongly up-regulates the expression of osteopontin
and its ligand aVb3 integrin in rat and human cardiac cells [57,58]. Inter-
estingly, elevated left ventricular osteopontin expression has been reported
in the Ren2 rat model characterized by high myocardial ANGII concen-
trations [49]. Monoclonal antibodies directed against either osteopontin
or aVb3 completely blocked the mitogenic effect of ANGII on cultured rat
Fig. 2. Potential pathways involved in angiotensin II (ANG II)-mediated fibrosis.
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fibroblast proliferation acting by an integrin-dependent pathway.
Stimulation of collagen synthesis
Although different signaling pathways of the AT1 receptor may subserve
direct ANGII-induced collagen synthesis in cardiac fibroblasts [59], re-
cent data suggest that the MAP/ER kinase pathway seems to play a major
role [60]. The end result of signaling mechanisms is activation of transcrip-
tion factors, which bind to various cis-acting elements in the regulatory
sequences of a1 and a2 collagen type I and a1 collagen type III genes [60,61].
This, in turn, couples with gene expression and the synthesis of collagen
types I and III precursor molecules [62,63].
A number of studies, however, provide strong evidence that ANGII indi-
rectly regulates collagen synthesis by cardiac fibroblasts by specific growth
factors [64]. The principal candidates include TGF-b1 and endothelin-1.
In fact, ANGII has been shown to induce collagen type I gene expression
by activation of TGF-b1 signaling pathways (eg, connective tissue growth
factor and Smad proteins) and these effects were blocked by the AT1 re-
ceptor antagonist losartan [65]. ANGII has been also shown to increase the
expression of TGF-b1 in cultured cardiac fibroblasts by stimulation of the
AT1 [54]. Recent data suggest that a Kru¨ppel-like zinc-finger transcription
factor 5 (also known as BTEB2 and IKLF) is critically involved in ANGII-
induced TGF-b1 expression, collagen synthesis, and development of car-
diac fibrosis [66]. Besides up-regulation of cardiac gene TGF-b1 expression,
ANGII has been reported to convert latent TGF-b1 to the active protein in
vivo in the heart [67].
Endothelin-1 is synthesized and released by cardiac fibroblasts in response
to the interaction of ANGII with the AT1 receptor [68] and has been shown
to stimulate the synthesis of collagen types I and III in these cells [69]. In
several rat models of arterial hypertension, blockade of endothelin receptors
is associated with decrease in left ventricular collagen accumulation [70,71].
There is some in vivo evidence that ANGII also influences post-
translational processing of cardiac fibrillar collagen. It has been shown that
ANGII infusion is associated with stimulation of prolyl 4-hydroxylase
(an enzyme that mediates hydroxylation of procollagen a chains in the
endoplasmic reticulum of cardiac fibroblasts) in the rat left ventricle [72]. In
addition, it has been reported that immunoreactive prolyl 4-hydroxylase
concentration decreases significantly in the ventricle of post–myocardial
infarction rats treated with the AT1 receptor antagonist losartan [73].
Inhibition of collagen degradation
In addition to collagen synthesis, ANGII stimulation of the AT1 receptor
has been shown to regulate collagen degradation by attenuating interstitial
collagenase activity in adult rat [54] and human [74] cardiac fibroblasts and
by enhancing TIMP-1 production in rat heart endothelial cells [75].
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cardiac collagen degradation (eg, TGF-b1 and plasminogen activator
inhibitor-1). Cell culture studies on human fibroblasts show that exposure
of these cells to TGF-b1 in the presence of other growth factors (eg, epi-
dermal growth factor and basic fibroblastic growth factor) resulted in down-
regulation of collagenase and up-regulation of TIMP-1 [76,77]. Similar
findings have been reported in the fibrotic myocardium of TGF-b1 transgenic
mice [78].
Activation of the AT1 receptor in human cardiac fibroblasts has been
shown to promote stimulation of plasminogen activator inhibitor-1 expres-
sion [79]. This stimulatory effect has been confirmed in the left ventricle of
ANGII-induced hypertensive rats [80]. Plasminogen activator inhibitor-1
inhibits the activation of collagenase and other matrix metalloproteinases
and thereby collagen degradation [81,82].
Interaction with aldosterone
Experimental studies have demonstrated the central role of aldosterone in
promoting cardiac fibrosis, probably through a direct action on the heart
mediated by cardiac mineralocorticoid receptors [83–85]. In fact, aldoste-
rone has been shown to stimulate collagen synthesis through the miner-
alocorticoid receptor in isolated cardiac fibroblasts [86]. In experimental
studies on rats with renovascular hypertension, hyperaldosteronism, or spon-
taneous hypertension, however, the aldosterone antagonist spironolactone
was able to prevent or reverse the development of myocardial fibrosis even
though the drug did not normalize blood pressure and did not prevent LVH
[8,43,87–89]. An increase in this mineralocorticoid may be a mechanism for
ANGII-induced cardiac fibrosis in some forms of arterial hypertension.
Interestingly, an increase in the density of AT1 receptors has been ob-
served in the heart of aldosterone-salt–treated rats [90]. In addition, the
AT1 receptor antagonist losartan prevents fibrosis and up-regulation of
collagen types I and III mRNAs in the heart of aldosterone-salt–treated rats
[91]. Taken together, these findings support the hypothesis that one mechan-
ism by which aldosterone induces cardiac fibrosis involves ANGII acting
through AT1 receptors. Because the production of aldosterone is activated
in the hypertrophied left ventricle of rats with spontaneous hypertension [92]
and hypertensive patients [93], it is possible that aldosterone contributes to
ANGII-mediated myocardial fibrosis in primary hypertension.
The potential clinical relevance of these interactions is given by several
observations. In essential hypertension, a low dose of the aldosterone anta-
gonist canrenone added to antihypertensive treatment has been shown
significantly to improve left ventricular diastolic function [94]. This improve-
ment, not accounted for by changes in blood pressure and left ventricular
mass, can be ascribed to a direct action of the drug on the myocardium. This
is further supported by recent studies showing that chronic administration
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with a reduction in the circulating levels of markers of collagen turnover in
patients with different cardiac diseases that evolve with myocardial fibrosis.
Summary
Structural homogeneity of cardiac tissue is governed by mechanical
and humoral factors that regulate cell growth, apoptosis, phenotype, and
extracellularmatrix turnover.ANGII has endocrine, autocrine, andparacrine
properties that influence the behavior of cardiac cells and matrix by AT1
receptor binding. Various paradigms have been suggested, including ANGII-
mediated up-regulation of collagen types I and III formation anddeposition in
cardiac conditions, such asHHD.Agrowing body of evidence, however, deals
with the potential role of aldosterone, either local or systemic, in inducing
cardiac fibrosis. Aldosterone might also mediate the profibrotic actions of
ANGII. To reduce the risk of heart failure that accompaniesHHD, its adverse
structural remodeling (eg, myocardial hypertrophy and fibrosis) must be
targeted for pharmacologic intervention. Cardioprotective agents must
reverse not only the exaggerated growth of cardiac cells, but also regress
existing abnormalities in fibrillar collagen.Available experimental and clinical
data suggest that agents interfering with ACE, the AT1 receptor, or the
mineralocorticoid receptor may provide such a cardioprotective effect.
References
[1] Weber KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair.
Semin Nephrol 1997;17:467–91.
[2] Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by
angiotensin II. Circ Res 1991;69:1185–95.
[3] Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA. Isoproterenol-induced
myocardial fibrosis in relation to myocyte necrosis. Circ Res 1989;65:657–70.
[4] Ratajska A, Campbell SE, Sun Y, Weber KT. Angiotensin II associated cardiac myocyte
necrosis: role of adrenal catecholamines. Cardiovasc Res 1994;28:684–90.
[5] Sun Y, Cleutjens JP, Diaz-Arias AA, Weber KT. Cardiac angiotensin converting enzyme
and myocardial fibrosis in the rat. Cardiovasc Res 1994;28:1423–32.
[6] Jugdutt BI, Amy RW. Healing after myocardial infarction in the dog: changes in infarct
hydroxyproline and topography. J Am Coll Cardiol 1986;7:91–102.
[7] Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and
renin-angiotensin-aldosterone system. Circulation 1991;83:1849–65.
[8] Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left
ventricles in experimental hypertension. Circ Res 1990;67:1355–64.
[9] Sun Y, Ratajska A, Zhou G, Weber KT. Angiotensin-converting enzyme and myocardial
fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med 1993;122:
395–403.
[10] Goldblatt H. Experimental hypertension induced by renal ischemia (Harvey Lecture).
Bull N Y Acad Med 1938;14:523–53.
[11] Hall CE, Hall O. Hypertension and hypersalimentation. I. Aldosterone hypertension.
Lab Invest 1965;14:285–94.
93A. Gonza´lez et al / Med Clin N Am 88 (2004) 83–97[12] Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am
Coll Cardiol 1989;13:1637–52.
[13] Weber KT. Stroma and the search for common ground. Plumbism or promiscuity?
Cardiovasc Res 1995;29:330–5.
[14] Mu¨ller GA, Schettler V, Mu¨ller CA, Strutz F. Prevention of progression of renal fibrosis:
How far are we? Kidney Int 1996;49(suppl 54):S75–82.
[15] Eddy AA. Interstitial macrophages as mediators of renal fibrosis. Exp Nephrol 1995;3:
76–9.
[16] Adler KB, Low RB, Leslie KO, Mitchell J, Evans JN. Biology of disease: contractile cells
in normal and fibrotic lung. Lab Invest 1989;60:473–85.
[17] Dunnill MS. Pulmonary fibrosis. Histopathology 1990;16:321–9.
[18] Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis
of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med 1993;328:1828–35.
[19] Pe´rez-Tamayo R. Collagen resorption in carrageenin granulomas. I. Collagenolytic
activity in in vitro explants. Lab Invest 1970;22:137–41.
[20] Kuncio GS, Neilson EG, Haverty T. Mechanisms of tubulointerstitial fibrosis. Kidney
Int 1991;39:550–6.
[21] Strutz F, Mu¨ller GA. On the progression of chronic renal disease. Nephron 1995;69:
371–9.
[22] Weber KT, Sun Y, Campbell SE, Slight SH, Ganjam VK, Griffing GT, et al. Chronic
mineralocorticoid excess and cardiovascular remodeling. Steroids 1995;60:125–32.
[23] Beltrami CA, FinatoN,RoccoM, FeruglioGA, Puricelli C, Cigola E, et al. Structural basis
of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994;89:151–63.
[24] Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative
analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardio-
myopathy. Br Heart J 1986;55:575–81.
[25] Olivetti G, Melissari M, Balbi T, Quaini F, Cigola E, Sonnenblick EH, et al. Myocyte
cellular hypertrophy is responsible for ventricular remodelling in the hypertrophied
heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res
1994;28:1199–208.
[26] Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy
due to chronic arterial hypertension in humans. J Hypertens 1998;16:1031–41.
[27] Ciulla M, Paliotti R, Hess DB, Tjhja E, Campbell SE, Magrini F, et al. Echocardio-
graphic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy
versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997;10:657–64.
[28] Schwartzkopff B, Brehm M, Mundehenke M, Strauer BE. Repair of coronary arterioles
after treatment with perindopril in hypertensive heart disease. Hypertension 2000;36:220–5.
[29] Brilla CG, Funck RC, Rupp RH. Lisinopril-mediated regression of myocardial fibrosis in
patients with hypertensive heart disease. Circulation 2000;102:1388–93.
[30] Querejeta R, Varo N, Lo´pez B, Larman M, Artin˜ano E, Etayo JC, et al. Serum carboxy-
terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hyper-
tensive heart disease. Circulation 2000;101:1729–35.
[31] Pardo-Minda´n FJ, Panizo A. Alterations in extracellular matrix of the myocardium in
essential hypertension. Eur Heart J 1993;14(suppl J):12–4.
[32] Burlew BS, Weber KT. Connective tissue and the heart: functional significance and
regulatory mechanisms. Cardiol Clin 2000;18:435–42.
[33] Bishop JE, Lindahl G. Regulation of cardiovascular collagen synthesis by mechanical
load. Cardiovasc Res 1999;42:27–44.
[34] Amanuma S, Sekiguchi M, Ogasawara S, Honda M, Hosoda S. Biventricular endo-
myocardial biopsy findings in essential hypertension of graded severity. Postgrad Med J
1994;70(suppl 1):S67–71.
[35] Pearlman ES,Weber KT, Janicki JS, PietraGG, FishmanAP.Muscle fiber orientation and
connective tissue content in the hypertrophied human heart. Lab Invest 1982;46:158–64.
94 A. Gonza´lez et al / Med Clin N Am 88 (2004) 83–97[36] Lo´pez B, Querejeta R, Varo N, Gonza´lez A, Larman M, Martı´nez Ubago JL, et al.
Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment
of the cardioreparative ability of antihypertensive treatment in hypertensive patients.
Circulation 2001;104:286–91.
[37] Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000;15:264–72.
[38] Dı´ez J, Lo´pez B, Gonza´lez A, Querejeta R. Clinical aspects of hypertensive myocardial
fibrosis. Curr Opin Cardiol 2001;16:328–35.
[39] Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to
angiotensin II or aldosterone infusion. Cardiovasc Res 1997;35:138–47.
[40] Jalil JE, Janicki JS, Pick R, Weber KT. Coronary vascular remodeling and myocardial
fibrosis in the rat with renovascular hypertension: response to captopril. Am J Hypertens
1991;4:51–5.
[41] Everett AD, Tufro-Mcreddie A, Fisher A, Gomez RA. Angiotensin receptor regulates
cardiac hypertrophy and transforming growth factor-b1 expression. Hypertension 1994;
23:587–92.
[42] Campbell JE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation
and phenotype expression in response to chronic administration of angiotensin II or
aldosterone. J Mol Cell Cardiol 1995;27:1545–60.
[43] Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of
myocardial fibrosis in primary and secondary aldosteronism. J Mol Cell Cardiol 1993;25:
563–75.
[44] Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H. Angiotensin II-induced
cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 1995;25:
1252–9.
[45] Crawford DC, Chobanian AV, Brecher P. Angiotensin II induces fibronectin expression
associated with cardiac fibrosis in the rat. Circ Res 1994;74:727–39.
[46] Lee MA, Bohm M, Paul M, Bader M, Ganten U, Ganten D. Physiological charac-
terization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol 1996;270:
E919–29.
[47] Bishop JE, Kiernan LA, Montgomery HE, Gohlke P, Mcewan JR. Raised blood
pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.
Cardiovasc Res 2000;47:57–67.
[48] Pinto YM, Pinto-Sietsma SJ, Philipp T, Engler S, Kossmehl P, Hocher B, et al. Reduction
in left ventricular messenger RNA for transforming growth factor beta (1) attenuates
left ventricular fibrosis and improves survival without lowering blood pressure in the
hypertensive TGR(mRen2)27 rat. Hypertension 2000;36:747–54.
[49] Rothermund L, Kreutz R, Kossmehl P, Fredersdorf S, Shakibaei M, Schulze-Tamzil G,
et al. Early onset of chondroitin sulfate and osteopontin expression in angiotensin II-
dependent left ventricular hypertrophy. Am J Hypertens 2002;15:644–52.
[50] Teisman AC, Pinto YM, Buikema H, Flesch M, Bohm M, Paul M, et al. Dissociation
of blood pressure reduction from end-organ damage in TGR(mREN2)27 transgenic
hypertensive rats. J Hypertens 1998;16:1759–65.
[51] Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in
genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial
coronary arteries. Circ Res 1991;69:107–15.
[52] Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, et al. Losartan inhibits
the postranscriptional synthesis of collagen type I and reverses left ventricular fibrosis in
spontaneously hypertensive rats. J Hypertens 1999;17:101–14.
[53] Varo N, Iraburu M, Varela M, Lo´pez B, Etayo JC, Dı´ez J. Chronic AT1 blockade
stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in
spontaneously hypertensive rats. Hypertension 2000;35:1197–202.
[54] Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy
of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1993;73:413–23.
95A. Gonza´lez et al / Med Clin N Am 88 (2004) 83–97[55] Bouzegrhane F, Thibault G. Is angiotensin II a proliferative factor of cardiac fibroblasts?
Cardiovasc Res 2002;53:304–12.
[56] Schnee JM, Hsueh WA. Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res
2000;46:264–8.
[57] Graf K, Neuss M, Stawowy P, Hsueh WA, Pleck E, Law RE. Angiotensin II and
alpha(V)beta(3) integrin expression in rat neonatal cardiac fibroblasts. Hypertension
2000;35:978–84.
[58] Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, et al. Osteopontin
is produced by rat cardiac fibroblasts and mediates AII-induced DNA synthesis and
collagen gel contraction. J Clin Invest 1996;98:2218–27.
[59] Dostal DE, Booz GW, Baker KM. Angiotensin II signaling pathways in cardiac fibro-
blasts: conventional versus novel mechanisms in mediating cardiac growth and function.
Mol Cell Biochem 1996;157:15–21.
[60] Tharaux PL, Chatziantoniou C, Fakhouri F, Dussaule JC. Angiotensin II activates
collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hyper-
tension 2000;36:330–6.
[61] Ghiggeri GM, Oleggini R, Musante L, Garidi G, Gusmano R, Ravazzolo R. A DNA
element in the a1 type III collagen promoter mediates a stimulatory response by
angiotensin II. Kidney Int 2000;58:537–48.
[62] Crabos M, Roth M, Hahn AW, Erne P. Characterization of angiotensin II receptors in
cultured adult rat cardiac fibroblasts: coupling to signaling systems and gene expression.
J Clin Invest 1994;93:2372–8.
[63] Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH. Identification of func-
tional angiotensin II receptors on cardiac fibroblasts. Circulation 1993;88:2849–61.
[64] Dostal DE. Regulation of cardiac collagen: angiotensin and cross-talk with local growth
factors. Hypertension 2001;37:841–4.
[65] Hao J, Wang B, Jones SC, Jassal DS, Dixon IM. Interaction between angiotensin II
and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol 2000;279:
H3020–30.
[66] Shindo T, Manabe I, Fukushima Y, Tobe K, Aizawa K, Miyamoto S, et al. Kru¨ppel-like
zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and
an essential regulator of cardiovascular remodeling. Nat Med 2002;8:856–63.
[67] Tomita H, Egahsira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, et al. Early
induction of transforming growth factor-b via angiotensin II type 1 receptors contributes
to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats.
Hypertension 1998;32:273–9.
[68] Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS. Angiotensin II stimulates cardiac
myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibro-
blasts. Cardiovasc Res 1998;40:352–63.
[69] Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on
collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993;27:2130–4.
[70] Ammarguellat F, Larouche II, Schiffrin EL. Myocardial fibrosis in DOCA-salt hyper-
tensive rats: effect of endothelin (ETA) receptor antagonism. Circulation 2001;103:
319–24.
[71] Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Hori M. Prevention of
diastolic heart failure by endothelin type A receptor antagonist through inhibition of
ventricular structural remodeling in hypertensive heart. J Hypertens 2002;20:753–61.
[72] Leipala JA, Takala TE, Ruskoaho H, Myllyla R, Kainulainen H, Hassinen IE, et al.
Transmural distribution of biochemical markers of total protein and collagen synthesis,
myocardial contraction speed and capillary density in the rat left ventricle in angiotensin
II-induced hypertension. Acta Physiol Scand 1988;133:325–33.
[73] Ju H, Zhao S, Jassal DS, Dixon IM. Effect of AT1 receptor blockade on cardiac collagen
remodeling after myocardial infarction. Cardiovasc Res 1997;35:223–32.
96 A. Gonza´lez et al / Med Clin N Am 88 (2004) 83–97[74] Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial matrix
remodeling in hypertensive heart disease. Adv Exp Mol Biol 1997;432:35–44.
[75] Chua CH, Hamdy RC, Chua BH. Angiotensin II induces TIMP-1 production in rat heart
endothelial cells. Biochem Biophys Acta 1996;1311:175–80.
[76] Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, et al.
Transforming growth factor beta modulates the expression of collagenase and metallo-
proteinase inhibitor. EMBO J 1987;6:1899–904.
[77] Chua CC, Chua BH, Zhao ZY, Krebs C, Diglio C, Perrin E. Effect of growth factors on
collagen metabolism in cultured human heart fibroblasts. Connect Tissue Res 1991;26:
271–81.
[78] Seeland U, Haeuseler C, Hinrichs R, Rosenkranz S, Pfitzner T, Scharffetter-Kochanek K,
et al. Myocardial fibrosis in transforming growth factor-b1 (TGF-b1) transgenic mice
is associated with inhibition of interstitial collagenase. Eur J Clin Invest 2002;32:
295–303.
[79] Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE, et al. Angiotensin II has
multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000;101:1130–7.
[80] Kobayashi N, Nakano S, Mita S, Kobayashi T, Honda T, Tsubokou Y, et al. Involve-
ment of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1
gene expression and cardiovascular remodeling in hypertensive rats. J Pharmacol Exp
Ther 2002;301:459–66.
[81] Yamamoto K, Saito H. A pathological role of increased expression of plasminogen acti-
vator inhibitor-1 in human or animal disorders. Int J Hematol 1998;68:371–85.
[82] Dollery CM, Mcewan JR, Henney AM. Matrix metalloproteinases and cardiovascular
diseases. Circ Res 1995;77:863–8.
[83] Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the
role of hormones. Hypertension 1994;23:869–77.
[84] Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and
cardiac fibrosis. J Clin Invest 1994;93:2578–83.
[85] Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for
cardiac aldosterone action: mineralocorticoid receptor and 11 beta-hydroxysteroid de-
hydrogenase in the human heart. Circulation 1995;92:175–82.
[86] Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat
cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;
26:809–20.
[87] Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing
myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993;71:12A–6A.
[88] Nicoletti A, Heudes D, Hinglais N, Appay MD, Philippe M, Sassy-Prigent C, et al. Left
ventricular fibrosis in renovascular hypertensive rats: effect of losartan and spirono-
lactone. Hypertension 1995;26:101–11.
[89] Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and
cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001;37:
662–7.
[90] Sun Y, Weber KT. Ang II and aldosterone receptor binding in rat heart and kidney:
response to chronic angiotensin II or aldosterone. J Lab Clin Med 1993;122:404–11.
[91] Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin
AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced
fibrosis. Hypertension 1999;33:981–6.
[92] Takeda Y, Yoneda T, Demure M, Miyamori I, Mabuchi H. Cardiac aldosterone pro-
duction in genetically hypertensive rats. Hypertension 2000;36:495–500.
[93] Yamamoto N, Yasue H, Mizuno Y, Yoshimura M, Fujii H, Nakayama M, et al.
Aldosterone is produced from ventricles in patients with essential hypertension. Hyper-
tension 2002;39:958–62.
97A. Gonza´lez et al / Med Clin N Am 88 (2004) 83–97[94] Grandi AM, Imperiale D, Santillo R, Barlocco E, Bertolini A, Guasti L, et al. Aldos-
terone antagonist improves diastolic function in essential hypertension. Hypertension
2002;40:647–52.
[95] MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen
turnover, improves heart rate variability and reduces early morning rise in heart rate in
heart failure patients. Cardiovasc Res 1997;35:30–4.
[96] Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix
turnover may contribute to survival benefit of spironolactone therapy in patients with
congestive heart failure: insights from the randomized aldactone evaluation study
(RALES). Rales Investigators. Circulation 2000;102:2700–6.
[97] Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Spiro-
nolactone inhibits the transcardiac extraction of aldosterone in patients with congestive
heart failure. J Am Coll Cardiol 2000;36:838–44.
[98] Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, et al. Relationship
between transcardiac extraction of aldosterone and left ventricular remodeling in pa-
tients with first acute myocardial infarction: extracting aldosterone through the heart
promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol
2001;38:1375–82.
[99] Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, et al. Immediate
administration of mineralocorticoid receptor antagonist spironolactone prevents post-
infarct left ventricular remodeling associated with suppression of a marker of myocardial
collagen synthesis in patients with first anterior acute myocardial infarction. Circulation
2003;107:2559–65.
[100] Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen syn-
thesis and progressive left ventricular enlargement after anterior myocardial infarction.
Am Heart J 2001;141:41–6.
